Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, begins Phase II trial

Lundbeck has presented Phase Ib clinical trial data for its investigational drug Lu AF28996, which is being studied for the treatment of advanced Parkinson's disease. The company has also initiated a Phase II trial for the same indication.